Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database

The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Arleigh McCurdy, Christopher P. Venner, Esther Masih-Khan, Martha Louzada, Richard LeBlanc, Michael Sebag, Kevin Song, Victor H. Jimenez-Zepeda, Rami Kotb, Moustafa Kardjadj, Hira Mian, Darrell White, Julie Stakiw, Muhammad Aslam, Anthony Reiman, Engin Gul, Donna Reece
Format:	Artigo
Język:	Inglês
Wydane:	MDPI AG 2022-03-01
Seria:	Current Oncology
Hasła przedmiotowe:	multiple myeloma relapsed/refractory pomalidomide carfilzomib sequence
Dostęp online:	https://www.mdpi.com/1718-7729/29/3/132
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!